Company intelligence / Profile preview

AM-Pharma

Utrecht, Utrecht, Netherlandsam-pharma.com ↗

Ownership: Private
Employees: ~23
Development stage: Phase 3

Overview

AM‑Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase. The lead program targets prevention and treatment of cardiac surgery-associated renal damage and rare disease hypophosphatasia. The company has initiated a Phase 2 trial for ilofotase alfa in CSA-RD. Pfizer previously acquired an option to purchase the remaining equity upon completion of certain milestones.

Therapeutic areas: Rare DiseasesCardiovascularNephrology
Modalities: Protein therapeuticsEnzyme therapy (recombinant human alkaline phosphatase)
Industry: Biotech

Drug pipeline

4 assets

ilofotase alfa

3 more assets in the full pipeline.

Request access →

Partnerships

Pfizer held an option to acquire the company after certain milestones were met

Beyond the preview

Go deeper on AM-Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-Pharma.

Explore the full profile